Tag Archives: health watchdog

UK medicine labels to be simplyfied

In what may be seen as further evidence that Britain is “dumbing down”, a health watchdog is calling for the labels on drugs and other medicines to be simplified to make them easier to understand.

The British National Formulary (BNF), which is the main source of information on medicines used by doctors, nurses and other health professionals, is recommending that labels be improved to make sure that they are clear and easy to understand by patients.

Medicines sold in the UK must be accompanied by a Patient Information Leaflet which provides detailed information about the product, its usage and side effects. But as Professor Theo Raynor of the University of Leeds points out, this is not the whole story.

“The leaflet may get lost which means that the label on the medicine plays a very important part in guiding people’s behaviour. It is vital therefore that wordings on labels are simple and straightforward” he said.

Professor Raynor carried out extensive user research into this issue, and concludes that the labels on medicines are vital sources of information and therefore need to be clear and easy to understand.

Medicine

Medicine

For instance many drug labels say that the medicine “may cause drowsiness” – but this may not always be understood. Changing the label to say “this medicine may make you sleepy” is much clearer for most people to understand.

As well as using simpler words, the BNF report also points out that some common phrases are ambiguous, for instance “avoid alcoholic drink” is not as clear a statement as “do not drink alcohol while taking this medicine”.


Professor Nick Barber, Professor of Pharmacy at London University, denies that these proposed changes are “dumbing down” – rather they are an attempt to prevent harm to patients. “When serious errors occur which cause harm to patients, it is often as a result of a series of minor failures at various stages. Therefore in taking more care about the wording of detailed instructions we can help improve the safety of medicines” he explained.

And this is not a small problem – “with two million prescriptions being issued every day, a small percentage improvement through labels being more understandable could make a significant impact” he added.

UK health watchdog NICE refuses to recommend Avastin

Cancer patients have expressed disappointment after the NHS drugs rationing body, Nice, refuses to recommend a bowel cancer drug for NHS patients.

The drug’s manufacturer’s, Roche, offered a complex deal which would see the price of the drug fixed at £20,800 for a year and would then be provided for free, along with a drug to be taken alongside it. When this was turned down Roche offered, in addition, to pay a payment to the NHS every time a new patient was started on the drug.

However, a panel of advisers at Nice, said this was a complex scheme that was likely to be expensive to administer and this threw into doubt the cost effectiveness of Avastin, also known as bevacizumab, for advanced bowel cancer.

Nice said the drug extended life by six weeks when compared with placebo.

Avastin

Avastin

Roche claiming that Avastin often shrank tumours sufficiently to enable them to be removed by surgery.

The health watchdog NICE says the cost of avastin – at about £21,000 per patient – does not justify its benefits.

It offers patients with advanced bowel cancer the chance of a few extra weeks or months of life.

Cancer charities hope the new cancer drug fund set up by the government will give greater access to the treatment.

Avastin, also known as bevacizumab, works by reducing the blood supply to a tumour, causing it to shrink or stop growing.


Avastin can extend the lives of bowel cancer sufferers by at least two years and often much longer.

However, the Government rationing body NICE ruled yesterday that it must stay banned because it is too expensive.
The result is that thousands of sufferers with the advanced form of the disease will not get the drug on the NHS – despite the fact that those living in France, Germany, Italy, Scandinavia, Australia and Canada are all prescribed it for free.

The veto could mean that Avastin is one of the first treatments to be paid for by the Government’s new emergency cancer drugs’ fund, which it has pledged to launch in October.